1 February 2024 false No description of principal activity Taxfiler 2024.6 11142238business:PrivateLimitedCompanyLtd2024-02-012025-01-31 111422382024-01-31 111422382024-02-012025-01-31 11142238business:AuditExemptWithAccountantsReport2024-02-012025-01-31 11142238business:FilletedAccounts2024-02-012025-01-31 111422382025-01-31 111422382024-01-31 11142238core:WithinOneYear2025-01-31 11142238core:WithinOneYear2024-01-31 11142238core:ShareCapitalcore:PreviouslyStatedAmount2025-01-31 11142238core:ShareCapitalcore:PreviouslyStatedAmount2024-01-31 11142238core:SharePremiumcore:PreviouslyStatedAmount2025-01-31 11142238core:SharePremiumcore:PreviouslyStatedAmount2024-01-31 11142238core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-01-31 11142238core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-01-31 11142238core:PreviouslyStatedAmount2025-01-31 11142238core:PreviouslyStatedAmount2024-01-31 11142238business:SmallEntities2024-02-012025-01-31 11142238business:Director42024-02-012025-01-31 11142238countries:EnglandWales2024-02-012025-01-31 11142238business:RegisteredOffice2024-02-012025-01-31 11142238core:PlantMachinery2024-02-012025-01-31 11142238core:ComputerEquipment2024-02-012025-01-31 11142238core:PlantMachinery2024-01-31 11142238core:ComputerEquipment2024-01-31 11142238core:PlantMachinery2025-01-31 11142238core:ComputerEquipment2025-01-31 111422382023-02-012024-01-31 iso4217:GBP xbrli:pure
Company Registration No. 11142238 (England and Wales)
Valogen Biosciences Limited Unaudited accounts for the year ended 31 January 2025
Valogen Biosciences Limited Unaudited accounts Contents
Page
- 2 -
Valogen Biosciences Limited Statement of financial position as at 31 January 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Tangible assets
13,413 
16,842 
Current assets
Debtors
9,395 
15,761 
Cash at bank and in hand
(12,320)
47,483 
(2,925)
63,244 
Creditors: amounts falling due within one year
(17,304)
(21,380)
Net current (liabilities)/assets
(20,229)
41,864 
Net (liabilities)/assets
(6,816)
58,706 
Capital and reserves
Called up share capital
11,773 
11,561 
Share premium
188,362 
163,481 
Profit and loss account
(206,951)
(116,336)
Shareholders' funds
(6,816)
58,706 
For the year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 18 April 2025 and were signed on its behalf by
Peter Elliott Luebcke Director Company Registration No. 11142238
- 3 -
Valogen Biosciences Limited Notes to the Accounts for the year ended 31 January 2025
1
Statutory information
Valogen Biosciences Limited is a private company, limited by shares, registered in England and Wales, registration number 11142238. The registered office is Upton Barton, South Milton, Kingsbridge, TQ7 3JF, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
20% Reducing Balance
Computer equipment
25% Straight Line
Government grants
Government grants, including research and development expenditure credits (RDEC), are recognised when there is reasonable assurance that the company will comply with the conditions attached to the grant and the grant will be received. Grants are recognised in profit or loss as other income in the period in which the related qualifying expenditure is incurred or the performance conditions are met. Grants are measured at the fair value of the amount receivable.
Research and development
Expenditure on research and development is written off in the year in which it is incurred.
Pension costs
The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are recognised in the profit and loss account when due.
Deferred taxation
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. A deferred tax asset is only recognised to the extent that it is probable that future taxable profits will be available against which the asset can be utilised.
- 4 -
Valogen Biosciences Limited Notes to the Accounts for the year ended 31 January 2025
4
Tangible fixed assets
Plant & machinery 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 February 2024
20,753 
427 
21,180 
At 31 January 2025
20,753 
427 
21,180 
Depreciation
At 1 February 2024
4,151 
187 
4,338 
Charge for the year
3,322 
107 
3,429 
At 31 January 2025
7,473 
294 
7,767 
Net book value
At 31 January 2025
13,280 
133 
13,413 
At 31 January 2024
16,602 
240 
16,842 
5
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
VAT
4,756 
7,889 
Other debtors
4,639 
7,872 
9,395 
15,761 
6
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Trade creditors
4,747 
550 
Taxes and social security
1,807 
- 
Other creditors
10,000 
20,000 
Loans from directors
- 
542 
Accruals
750 
288 
17,304 
21,380 
7
Average number of employees
During the year the average number of employees was 3 (2024: 3).
- 5 -